Fused Or Hybrid Cell, Per Se Patents (Class 435/346)
-
Publication number: 20090215711Abstract: The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that present novel therapeutic targets against cancer. The present invention further provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer.Type: ApplicationFiled: April 30, 2004Publication date: August 27, 2009Applicant: Sagres Discovery, Inc.Inventors: David W. Morris, Marc S. Malandro, Albert Lai, Christin Tse, Ali Fattaey
-
Publication number: 20090214565Abstract: The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFN?”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFN? protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFN? subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFN? related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.Type: ApplicationFiled: February 6, 2009Publication date: August 27, 2009Inventors: Jacques BANCHEREAU, Kiley Prilliman, Virginia Pascual, Anna Karolina Palucka
-
Patent number: 7579447Abstract: Lipoprotein Lipase like polypeptides, nucleic acids encoding said polypeptides, antisense sequences, and antibodies to said polypeptides are disclosed. Also disclosed are methods for the preparation of said polypeptides in a recombinant system and for the use of said polypeptides to screen for agonists and or antagonists of said polypeptides. Also disclosed are methods and compositions for the treatment of disorders of lipid metabolism.Type: GrantFiled: March 7, 2006Date of Patent: August 25, 2009Assignee: Aventis Pharmaceuticals Inc.Inventors: Michael C. Jaye, Kim-Anh Thi Doan, John A. Krawiec, Kevin J. Lynch, Dilip V. Amin, Victoria J. South
-
Publication number: 20090208506Abstract: The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter and Pseudomonas. The present invention further provides methods of treating inflammatory bowel disease (IBD) and methods of treating enterobacterial infections using anti-flagellin antibodies in humans, other animals and birds.Type: ApplicationFiled: September 5, 2008Publication date: August 20, 2009Applicants: Inotek Pharmaceuticals Corporation, Yeda Research and Development Co., Ltd.Inventors: Nurit Rachamim, Andrew L. Salzman, Kanneganti Murthy
-
Publication number: 20090202556Abstract: An object of the present invention is to provide a monoclonal antibody which is useful as a diagnostic agent or a therapeutic agent for a disease relating to a polypeptide encoded by Claudin-4 (hereinafter referred to as “CLDN4”) gene or a polypeptide encoded by a Claudin-3 (hereinafter referred to as “CLDN3”) gene, or a method for using the same.Type: ApplicationFiled: March 17, 2008Publication date: August 13, 2009Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: So OHTA, Hiroshi ANDO, Masayo SUZUKI, Shinobu KAWAMOTO, Mariko NAKANO, Kazuyasu Nakamura
-
Publication number: 20090202561Abstract: The invention provides the identification and characterization of disease and cancer-associated antigen, RAAG10. The invention also provides a family of monoclonal antibodies that bind to antigen RAAG10, methods of diagnosing and treating various human cancers and diseases that express RAAG10.Type: ApplicationFiled: March 27, 2009Publication date: August 13, 2009Inventors: Jennie P. MATHER, Ronghao Li, Zhuangyu Pan, Penelope E. Roberts
-
Publication number: 20090202562Abstract: Antibodies and antibody fragments that bind to the receptor GFRalpha3 and inhibit formation of a Neublastin-GFRalpha3-Ret ternary complex are disclosed. Also disclosed are methods of using the antibodies and antibody fragments to inhibit phosphorylation of Ret in a cell and treat disorders and in a subject.Type: ApplicationFiled: June 16, 2006Publication date: August 13, 2009Applicant: BIOGEN IDEC MA INC.Inventors: Dane S. Worley, Dinah Wen-Yee Sah, Katherine W. Seamans
-
Publication number: 20090191197Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: ApplicationFiled: January 21, 2009Publication date: July 30, 2009Inventors: David S.F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto
-
Publication number: 20090191187Abstract: The present invention relates to antibodies against interleukin-1 receptor (IL-1R), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. The antibodies of the present invention are particularly useful for treating a variety of inflammatory diseases including, but not limited to, rheumatoid arthritis.Type: ApplicationFiled: February 13, 2009Publication date: July 30, 2009Inventors: Ilse Bartke, Francis Carr, Richard Anthony Chizzonite, Elsie M. Eugui, Georg Fertig, Anita Hamilton, Martin Lanzendoerfer, Petra Rueger, Ralf Schumacher, Theresa Patricia Truitt
-
Publication number: 20090191190Abstract: Anti-A? globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies. The present invention relates to anti-A? globulomer antibodies having a binding affinity to A?(20-42) globulomer that is greater than the binding affinity of the antibody to A?(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors, methods of producing said antibodies, compositions comprising said antibodies, therapeutic and diagnostic uses of said antibodies and corresponding methods relating to Alzheimer's disease and other amyloidoses.Type: ApplicationFiled: November 30, 2006Publication date: July 30, 2009Inventors: Stefan Barghorn, Heinz Hillen, Boris Labkovsky, Andreas R. Striebinger, Patrick Keller, Ulrich Ebert
-
Publication number: 20090191214Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.Type: ApplicationFiled: December 8, 2008Publication date: July 30, 2009Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
-
Publication number: 20090191572Abstract: The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascular endothelium.Type: ApplicationFiled: January 15, 2008Publication date: July 30, 2009Applicant: Cancer Research Technology LimitedInventors: Roy Bicknell, Lukasz Huminiecki
-
Publication number: 20090181410Abstract: The present invention relates in part to antibodies for the performance of immunoassays to determine whether a test sample, such as a food sample, contains tissue derived from a Pangasius species of fish, such as tra or basa. Such antibodies, either alone or in combination, specifically bind to a thermostable antigen from a Pangasius species. The present invention further relates to methods for conducting immunoassays that may use such antibodies to detect the presence of a test antigen in a test sample that is derived from a Pangasius species of fish, such as tra or basa. In addition, such antibodies may be part of a test kit that may also contain one or more test reagent(s) or items of test equipment.Type: ApplicationFiled: September 19, 2008Publication date: July 16, 2009Applicant: FLORIDA STATE UNIVERSITY RESEARCH FOUNDATIONInventor: Yun-Hwa Peggy Hsieh
-
Publication number: 20090176260Abstract: Embodiments of the present disclosure include double-fusion human embryonic stem cells, methods of imaging double-fusion human embryonic stem cells, double-fusion polynucleotides, double-fusion proteins, triple-fusion human embryonic stem cells, methods of imaging triple-fusion human embryonic stem cells, triple-fusion polynucleotides, triple-fusion proteins, methods of monitoring the progression of human embryonic stem cells, methods of making isolated double-fusion human embryonic stem cells, methods of making isolated triple-fusion human embryonic stem cells, and the like.Type: ApplicationFiled: December 4, 2008Publication date: July 9, 2009Inventors: Joseph Ching-Ming Wu, Feng Cao
-
Publication number: 20090155279Abstract: An object of the present invention is to provide a protein or peptide antigen and an antibody against it, for use in the diagnosis, prevention, or treatment of diseases associated with Pseudomonas aeruginosa. According to the present invention, there is provided a protein or peptide derived from Pseudomonas aeruginosa outer membrane protein PA5158 and an antibody against it, for use in the diagnosis, prevention, or treatment of diseases associated with Pseudomonas aeruginosa.Type: ApplicationFiled: October 27, 2006Publication date: June 18, 2009Inventors: Jiro Tanaka, Fukuichi Ohsawa, Takafumi Okutomi, Hiroshi Nagaso, Masashi Kumagai, Takahisa Suzuki, Keiko Otsuka
-
Patent number: 7547441Abstract: A method is described for detecting, visualizing, or treating cells, particularly cancerous cells, that express a uPA/uPAR complex. The method employs a PAI-2 conjugate molecule that comprises PAI-2 or a functional derivative, homologue, analogue, chemical equivalent or mimetic thereof, which PAI-2 is bound, linked, or otherwise associated with a toxin or label.Type: GrantFiled: February 23, 2001Date of Patent: June 16, 2009Assignees: PAI-2 Pty Limited, University of Wollongong, Medical Scitec Australia Pty LtdInventors: Marie Ranson, Barry John Allen, Clive Leighton Bunn
-
Patent number: 7547438Abstract: Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells. Several such monoclonal antibodies are provided, and cell lines producing them have been deposited at the American Type Culture Collection.Type: GrantFiled: December 20, 2006Date of Patent: June 16, 2009Assignee: Pangenetics BVInventors: David Thomas, Mark De Boer, Pieter C. J. M. Res, Peter J. Simone
-
Publication number: 20090148880Abstract: The invention relates to a method for treating a biological cell (1) including a cytoskeleton (3) enveloped by a cell membrane (2). The method includes the following steps: the biological cell (1) and a tool (10) are mutually oriented such that the tool (10) comes into contact with the biological cell (1); the tool (10) and the biological cell (1) are displaced in relation to each other; and a gap is formed in the molecular composite of the cell membrane (2) of the biological cell (1). During the displacement of the tool (10), the cytoskeleton (3) of the biological cell (1) has a state of equilibrium. The invention also relates to a cell manipulator for carrying out the inventive method.Type: ApplicationFiled: November 2, 2005Publication date: June 11, 2009Applicant: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Inventors: Günter Fuhr, Hagen Thielecke
-
Publication number: 20090148453Abstract: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.Type: ApplicationFiled: October 15, 2007Publication date: June 11, 2009Inventors: Walter Newman, Shixin Qin, Theresa L. O'Keefe, Robert A. Obar
-
Publication number: 20090136964Abstract: An antibody which reacts with N-acetylheparosan and heparan sulfate that is derived from bovine kidney but does not substantially react with heparan sulfate derived from a murine Engelbreath-Holm-Swam tumor tissue, the antibody being produced with a hybridoma which is prepared using a substance composed of a protein and N-acetylheparosan bound to the protein.Type: ApplicationFiled: March 31, 2006Publication date: May 28, 2009Applicant: Seikagaku corporation Central research LaboratorieInventors: Kiyoshi Suzuki, Takeshi Ishimaru, Koji Yamamoto
-
Patent number: 7537763Abstract: An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.Type: GrantFiled: December 5, 2006Date of Patent: May 26, 2009Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Toshifumi Mikayama, Hitoshi Yoshida, Walker R. Force, Xingjie Chen, Nobuaki Takahashi
-
Publication number: 20090123462Abstract: The present invention relates to the use of Fibroblast-Growth Factor Receptor (FGFR) agonists for the diagnosis, prevention and/or treatment of pathological conditions including, but not limited to hyperproliferative disorders, bone diseases and vascular diseases. Particularly, the use of FGFR-4 agonists, e.g. anti-FGFR-4 antibodies is described. Further, the invention relates to a pharmaceutical composition comprising the agonist as described above and a screening procedure.Type: ApplicationFiled: October 24, 2008Publication date: May 14, 2009Inventors: Johannes Bange, Axel Ullrich
-
Publication number: 20090124022Abstract: The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies.Type: ApplicationFiled: April 16, 2008Publication date: May 14, 2009Applicant: Abbott LaboratoriesInventors: Larry G. Birkenmeyer, Suresh M. Desai, David J. Hawksworth, Edward T. Olejniczak, Qiaoqiao Ruan, Robert W. Siegel, Sergey Y. Tetin, Bryan C. Tieman, Bailin Tu, Joan D. Tyner, Robert N. Ziemann, Lowell J. Tyner
-
Publication number: 20090117121Abstract: An object of the present invention is to provide a protein or peptide antigen and an antibody against it, for use in the diagnosis, prevention, or treatment of diseases associated with Pseudomonas aeruginosa. According to the present invention, there is provided a protein or peptide derived from Pseudomonas aeruginosa outer membrane protein PA0427 and an antibody against it, for use in the diagnosis, prevention, or treatment of diseases associated with Pseudomonas aeruginosa.Type: ApplicationFiled: March 30, 2007Publication date: May 7, 2009Inventors: Jiro Tanaka, Fukuichi Ohsawa, Takafumi Okutomi, Hiroshi Nagaso, Masahi Kumagai, Takashisa Suzuki, Keiko Otsuka
-
Publication number: 20090117095Abstract: Provided are isolated and purified preparations of a combination of a light chain antibody gene and a heavy chain antibody gene, where the light chain and heavy chain antibody genes are the same among more than one patient with B cell chronic lymphocytic leukemia (B-CLL). Vectors comprising those genes and cells comprising those vectors are also provided, as are isolated and purified antibodies encoded by the antibody genes. Anti-idiotype antibodies, peptides, and aptamers that bind to the antigen-binding region of an antibody encoded by the antibody genes are additionally provided, as are multimeric molecules comprising multiple binding sites that bind to the antigen-binding region of an antibody encoded by the antibody genes.Type: ApplicationFiled: October 8, 2004Publication date: May 7, 2009Inventors: Bradley T. Messmer, Nicholas Chiorazzi, Emilia Albesiano
-
Publication number: 20090104115Abstract: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: ApplicationFiled: October 2, 2008Publication date: April 23, 2009Inventors: David S.F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto
-
Publication number: 20090104232Abstract: The invention provides a gene transfer vector for inducing an immune response against Yersinia pestis in a mammal. The gene transfer vector comprises a nucleic acid sequence encoding an immunogenic portion of one or more proteins of Yersinia pestis and/or a nucleic acid sequence encoding a monoclonal antibody directed against Yersinia pestis. The invention further provides a method of producing an immune response against Yersinia pestis in a mammal comprising administration of the gene transfer vector to the mammal. The invention also provides a monoclonal antibody directed against the Virulence (V) antigen of Y. pestis, as well as a hybridoma cell line producing same and a nucleic acid sequence encoding same.Type: ApplicationFiled: September 25, 2008Publication date: April 23, 2009Applicant: Cornell UniversityInventors: Ronald G. Crystal, Julie L. Boyer
-
Publication number: 20090098572Abstract: The present invention provides a breast cancer resistance polynucleotide and protein of Macaca mulata (rhesus monkey) and uses thereof. The present invention also provides anti-BCRP antibodies and uses thereof, particularly as a hematopoietic stem cell marker.Type: ApplicationFiled: November 6, 2008Publication date: April 16, 2009Inventor: Naoko TAKEBE
-
Publication number: 20090098125Abstract: The present invention is directed to the diagnosis and treatment of diseases, preferably the inhibition of tumor growth and its progression to metastatic sites, through the inhibition of the production of PTHrP, its isoforms or PTHrP signalling. The present invention is also directed to methods of inhibiting the PTHrP1-173 isoform through antagonists thereof, including monoclonal antibodies and siRNA directed there against. The invention may be applicable to many disease states, including but not limited to several types of cancer (such as breast, lung, prostate, melanoma and squamous) expressing PTHrP and its isoforms, alone or in combination with other therapeutic agents.Type: ApplicationFiled: August 17, 2007Publication date: April 16, 2009Inventors: Richard Kremer, Dao Chao Huang
-
Patent number: 7517966Abstract: The invention relates to a novel compound termed NKp30 that is selectively expressed by all mature NK cells and that is involved in human natural cytoxicity as an activatory receptor, to new antibodies that bind to the NKp30 structure, and to the pharmaceutical and medicinal uses thereof.Type: GrantFiled: May 25, 2005Date of Patent: April 14, 2009Assignees: Innate Pharma S.A.S., Universita Di GenovaInventors: Alessandro Moretta, Cristina Bottino, Roberto Biassoni
-
Publication number: 20090087435Abstract: isolated chimeric proteins including up to ten copies of peptides, polypeptides or protein domains inserted in the amino termini of the Brucella spp. Lumazine synthase enzyme. Isolated nucleotide sequences codifying the chimeric proteins. Vectors, plasmids and transformed cells used for expressing the proteins. Monoclonal and polyclonal antibodies induced by the chimeric proteins. Hybridomas producing the monoclonal antibodies. Vaccines and pharmaceutical compounds including the chimeric proteins, nucleotide sequences and antibodies. A method to induce an immune response in higher organisms including the administration of effective amounts of the vaccines and pharmaceutical compounds. Biosensors including the chimeric proteins. Protein conjugates formed by the chimeric proteins and a ligand bound by means of covalent and noncovalent bonds.Type: ApplicationFiled: June 3, 2005Publication date: April 2, 2009Applicant: GOLDGENE LLCInventors: Fernando Goldbaum, Diego Andres Laplagne, Vanesa Zylberman, Patricio Craig, Paula Mercedes Berguer, Natalia Ainciart, Carlos Alberto Fossati, Carlos Alejandro Velikovsky, Juliana Cassataro, Guillermo Giambartolomei
-
Publication number: 20090081809Abstract: The present invention provides a monoclonal antibody displaying excellent specificity against heparan sulfate saccharide chains for the analysis of heparan sulfate saccharide chains specific to dentin. The invention also provides a method of evaluating reproductive dentin using the monoclonal antibody. The anti-heparan sulfate monoclonal antibody reacts against dentin-derived heparan sulfate and in particular the anti-heparan sulfate monoclonal antibody reacts strongly and specifically with uncalcified predentin regions. In the method of evaluating dentin, the antibody is reacted against an isolated dentin-derived sample and the reaction is used in order to evaluate the development of dentin.Type: ApplicationFiled: August 19, 2008Publication date: March 26, 2009Inventors: Akiko Hisada, Ryossuke Takahashi, Hiroko Hanzawa
-
Publication number: 20090074728Abstract: The present invention relates to the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and/or isolating adult multipotential cells. The present invention also relates to cell populations enriched by methods of the present invention and therapeutic uses of these cells.Type: ApplicationFiled: April 12, 2006Publication date: March 19, 2009Inventors: Stan Gronthos, Andrew Christopher William Zannettino, Paul John Simmons
-
Publication number: 20090074661Abstract: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.Type: ApplicationFiled: July 21, 2008Publication date: March 19, 2009Inventors: Wenfeng Xu, Wayne Kindsvogel, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavur V. Sivakumar, Margaret D. Moore
-
Patent number: 7504255Abstract: The present invention provides a cell line capable producing infectious hepatitis C virus 1a (HCV 1a) particles in culture. Disclosed are compositions and methods for an HCV 1a (clone H77) transfected immortal human hepatocyte (IHH) capable of generating infectious HCV 1a virus particles in culture. Also disclosed are methods of using the cell line, or HCV 1a virus particles derived from said cell line, to screen for potential therapeutic agents which interfere with HCV 1a virus propagation to treat hepatic disease.Type: GrantFiled: August 17, 2006Date of Patent: March 17, 2009Assignee: Saint Louis UniversityInventors: Ratna Ray, Ranjit Ray, Arnab Basu, Tatsuo Kanda
-
Patent number: 7504254Abstract: Novel bactericidal antibodies against Neisseria meningitidis serogroup B (“MenB”) are disclosed. The antibodies either do not cross-react or minimally cross-react with host tissue polysialic acid and hence pose minimal risk of autoimmune activity. The antibodies are used to identify molecular mimetics of unique epitopes found on MenB or E. coli K1. Examples of such peptide mimetics are described that elicit serum antibody capable of activating complement-mediated bacteriolysis of MenB. Vaccine compositions containing such mimetics can be used to prevent MenB or E. coli K1 disease without the risk of evoking autoantibody.Type: GrantFiled: October 5, 2005Date of Patent: March 17, 2009Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Dan M. Granoff, Gregory R. Moe
-
Publication number: 20090068100Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: ApplicationFiled: August 22, 2008Publication date: March 12, 2009Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto
-
Publication number: 20090068182Abstract: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: ApplicationFiled: August 13, 2008Publication date: March 12, 2009Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto, Alison L. Ferry
-
Publication number: 20090061459Abstract: The invention discloses nearly 443 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human carcinoma, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Protein kinases (including Serine/Threonine dual specificity, and Tyrosine kinases), Adaptor/Scaffold proteins, Transcription factors, Phospoatases, Tumor supressors, Ubiquitin conjugating system proteins, Translation initiation complex proteins, RNA binding proteins, Apoptosis proteins, Adhesion proteins, G protein regulators/GTPase activating protein/Guanine nucleotide exchange factor proteins, and DNA binding/replication/repair proteins, as well as other protein types.Type: ApplicationFiled: February 29, 2008Publication date: March 5, 2009Inventors: Roberto Polakiewicz, Ailan Guo, Albrecht Moritz, Klarisa Rikova, Kimberly Lee, Erik Spek, Yu Li, Charles Farnsworth
-
Publication number: 20090047285Abstract: Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.Type: ApplicationFiled: January 24, 2008Publication date: February 19, 2009Inventors: Austin Gurney, Aaron Sato, Maureen Fitch-Bruhns
-
Publication number: 20090041659Abstract: The invention described herein provides for human antibodies produced in non-human animals that specifically bind to lipopolysaccharide (LPS) from strains Fisher Devlin (International Serogroups) It-2 (011), It-3 (02), It-4 (01), It-5 (010), It-6 (07), PA01 (05), 170003 (02), IATS016 (02/05), and 170006 (02). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein.Type: ApplicationFiled: December 3, 2004Publication date: February 12, 2009Inventor: John R. Schreiber
-
Publication number: 20090041756Abstract: A novel gene (designated 121P1F1) and its encoded protein are described. While 121P1F1 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including prostate, bladder, kidney, brain, bone, cervical, uterine, ovarian, breast, pancreatic, stomach, colon, rectal, leukocytic, liver and lung cancers. Consequently, 121P1F1 provides a diagnostic and/or therapeutic target for cancers, and the 121P1F1 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.Type: ApplicationFiled: December 7, 2007Publication date: February 12, 2009Inventors: PIA M. CHALLITA-EID, RENE S. HUBERT, STEVEN CHAPPELL MITCHELL, ARTHUR B. RAITANO, MARY FARIS, DANIEL E.H. AFAR, AYA JAKOBOVITS
-
Patent number: 7488807Abstract: Monoclonal antibodies, and antigen binding fragments thereof, which bind to Protein A of Staphylococcus aureus are provided.Type: GrantFiled: November 22, 2006Date of Patent: February 10, 2009Assignee: 3M Innovative Properties CompanyInventors: Patrick A. Mach, Mara S. Reif-Wenner
-
Publication number: 20090035307Abstract: The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.Type: ApplicationFiled: November 26, 2007Publication date: February 5, 2009Inventors: STEFAN BARGHORN, Heinz Hillen, Andreas R. Striebinger, Boris Labkovsky, Ulrich Ebert, Patrick Keller
-
Publication number: 20090035299Abstract: Methods and compositions for diagnosing, detecting and treating a colon disease associated with differential expression of MABA1 in comparison to healthy cells. Also provided are antagonists or agonists of MABA1, and methods for screening agents that modulate the MABA1 level or activity in vivo or in vitro.Type: ApplicationFiled: June 5, 2008Publication date: February 5, 2009Applicant: APPLERA CORPORATIONInventors: Candy Lee, Charles E. Birse, Yeounjin Kim
-
Publication number: 20090017020Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.Type: ApplicationFiled: June 6, 2008Publication date: January 15, 2009Inventors: Robert S. AMES, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
-
Publication number: 20090017044Abstract: This invention provides antibodies to the prolactin receptor, particularly the human prolactin receptor. Preferred antibodies are capable of blocking prolactin binding to the prolactin receptor, inhibiting signaling through the prolactin receptor, and/or inhibiting proliferation of cancer cells induced by prolactin. Also provided are nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and uses of the antibodies and nucleic acids.Type: ApplicationFiled: April 30, 2008Publication date: January 15, 2009Applicant: BIOGEN IDEC MA INC.Inventors: Brian Elenbaas, Matthew B. Jarpe, Steven D. Miklasz, Stephen E. Fawell
-
Publication number: 20090017027Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than said antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.Type: ApplicationFiled: July 3, 2008Publication date: January 15, 2009Applicant: MACROGENICS, INC.Inventors: Scott Koenig, Maria Concetta Veri
-
Patent number: 7476540Abstract: The present invention relates to monoclonal antibodies specifically binding to a membrane antigen of human mesenchymal stem cells, hybridoma cell lines producing the same, and methods for identifying or isolating human mesenchymal stem cells using the same. The monoclonal antibodies of this invention exhibit excellent specificity to human mesenchymal stem cells, inter alia, bone marrow-derived human mesenchymal stem cells, so that it allows for the identification and isolation of human mesenchymal stem cells with much higher specificity.Type: GrantFiled: January 10, 2006Date of Patent: January 13, 2009Assignee: Seoul National University Industry FoundationInventors: Yeong-Wook Song, Hyun-Jung Yoo, Sung-Soo Yoon, Seonyang Park, Weon-Seo Park, Dong-Jo Kim, Eun-Bong Lee
-
Publication number: 20090010924Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.Type: ApplicationFiled: March 21, 2008Publication date: January 8, 2009Applicant: GENENTECH, INC.Inventors: Lawren Wu, Mercedesz Balazs, Hans Brightbill, Andrew Chan, Yvonne Chen, Anan Chuntharapai, Mark Dennis, Terence Wong